Spartina Biotechnologies

Dear Investor,

Welcome to Spartina Biotechnologies, a company devoted to protecting people from viral infections and their impacts on global health.

The scientists at Spartina Biotechnologies are developing a safe, fast-acting anti-viral technology that could serve as a treatment and preventative for COVID-19.  When successful, our country and the world will be taking a Spartina therapeutic to stop the progression of COVID-19 and prevent an infection from the virus.

Given public reluctance about vaccines, antiviral treatment medications are an important adjunct in fighting the pandemic, as well as a rapid response solution for emerging viral diseases. Recent public polls have shown that only about 50% of people in the U.S. may be willing to take a Covid vaccine. 

The medication, created by our proprietary SIREN™ technology, has no anticipated side effects, which means it is as safe as any medication could be. It will be manufactured in an injectable or ingestible formulation and we intend to bring it through clinicals and to market as quickly as possible (2022).

The next few months are crucial as we complete the Proof of Technology (POT) in the lab and Proof of Concept (POC). We hope to move on to manufacturing and have an FDA approved product going to market in late 2022.

If you are interested in being part of this life-changing technology, something that could help eradicate COVID-19 and move on to tackle other viruses and other diseases in human medicine, please contact us today.

Let’s change the world of viral diseases together.

Paul Laur
CEO, Co-founder

Keara Sauber
President